Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04914845 · ClinicalTrials.gov registry record · Phase 1
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04914845 is a Phase 1 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse that has completed, run by University of Colorado, Denver. The registered enrollment target is 16 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04914845, a Phase 1 study of Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability of oral KPT-9274 for the treatment of patients with relapsed or refractory acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG KPT-9274
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2025-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04914845
The ClinicalTrials.gov registry entry for NCT04914845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (86% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which KPT-9274 is the first listed.
NCT04914845 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04914845 about?
NCT04914845 is a clinical study titled "KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia". This study will evaluate the safety and tolerability of oral KPT-9274 for the treatment of patients with relapsed or refractory acute myeloid leukemia.
What is the current status of trial NCT04914845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-08-27. Estimated completion is 2025-10-22.
What conditions does trial NCT04914845 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory.
What interventions are being tested in trial NCT04914845?
The interventions under investigation include: KPT-9274 (DRUG).
Who is sponsoring clinical trial NCT04914845?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04914845 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.